← All organizations

bluebird bio

For profitContributed to NMEWebsite ↗

Also known as: bluebird bio | bluebird bio Inc. | bluebird bio, Inc. | Bluebird Bio Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Dec 8, 2023

Timeline

1990s

Jun 1, 1992
bluebird bio— Founded

2010s

Jul 1, 2014
Pregenen— Acquired

2020s

Sep 16, 2022
elivaldogene autotemcel— NDA Secondary Org
Dec 8, 2023
lovotibeglogene autotemcel— NDA Organization

Drugs by trial phase (10 distinct, 14 trials)

Phase 3 (3 own, 0 via acquisition)

Phase 2 (3 own, 0 via acquisition)

Phase 1 (4 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (3)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Pregenen

Recent trials (23)

NCT05353647CollaboratorPhase 2Jul 12, 2022
NCT05445128CollaboratorPhase 2Jun 24, 2022
NCT05105152CollaboratorPhase 1Nov 15, 2021
NCT04293185Study directorPhase 3Feb 14, 2020
NCT04293185Lead sponsorPhase 3Feb 14, 2020
NCT03852498Lead sponsorPhase 3Jan 24, 2019
NCT03852498Study directorPhase 3Jan 24, 2019
NCT03131934CollaboratorEarly Phase 1Sep 15, 2017
NCT03274219Study directorPhase 1Aug 16, 2017
NCT03274219Lead sponsorPhase 1Aug 16, 2017
NCT03207009Study directorPhase 3Jun 8, 2017
NCT03207009Lead sponsorPhase 3Jun 8, 2017
NCT02906202Lead sponsorPhase 3Jul 1, 2016
NCT02906202Study directorPhase 3Jul 1, 2016
NCT02658929Lead sponsorPhase 1Jan 1, 2016

Details

Founded: Cambridge, MA, US Jun 1, 1992
First NDA: Aug 17, 2022
Last known activity: Dec 8, 2023

Designations held

Orphan drug
Breakthrough therapy
Accelerated approval